Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04222062 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
A Phase 2 study of Brain Tumor - Metastatic, sponsored by University of Nebraska.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 2
- Study locations
NCT04222062 is a Phase 2 study of Brain Tumor - Metastatic that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 100 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT04222062, a Phase 2 study of Brain Tumor - Metastatic, is actively recruiting participants, sponsored by University of Nebraska.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.
Conditions Studied
Interventions
- DRUG Carmustine 7.7Mg Wafer
Study Locations (2)
Michigan
- Henry Ford - Detroit
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-11-06 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04222062
The ClinicalTrials.gov registry entry for NCT04222062 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Tumor - Metastatic appearing as the primary indexed condition, and to 1 intervention - of which Carmustine 7.7Mg Wafer is the first listed.
NCT04222062 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Michigan, Nebraska.
Frequently Asked Questions
What is clinical trial NCT04222062 about?
NCT04222062 is a clinical study titled "A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease". This study is being done to see if adding GLIADEL to the site where the tumor was removed works as well as just having the tumor removed with radiation treatment done within six weeks after the surgery to keep the cancer from coming back.
What is the current status of trial NCT04222062?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-11-06. Estimated completion is 2028-12.
What conditions does trial NCT04222062 study?
This clinical trial studies the following conditions: Brain Tumor - Metastatic.
What interventions are being tested in trial NCT04222062?
The interventions under investigation include: Carmustine 7.7Mg Wafer (DRUG).
Who is sponsoring clinical trial NCT04222062?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04222062 being conducted?
This trial has 2 study locations across Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor - Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.